Guidance for substantiating the evidence for beneficial effects of probiotics: probiotics in chronic inflammatory bowel disease and the functional disorder irritable bowel syndrome.
about
Indication for Co-evolution of Lactobacillus johnsonii with its hostsAntioxidant therapy for treatment of inflammatory bowel disease: Does it work?Identification and characterisation of an iron-responsive candidate probioticSpontaneous remission of Crohn's disease following a febrile infection: case report and literature review.Differential Toll-like receptor recognition and induction of cytokine profile by Bifidobacterium breve and Lactobacillus strains of probiotics.Test-based exclusion diets in gastro-esophageal reflux disease patients: a randomized controlled pilot trial.Intestinal microbiota and blue baby syndrome: probiotic therapy for term neonates with cyanotic congenital heart diseaseCurrent and emerging drugs for the treatment of inflammatory bowel disease.Lactobacillus amylovorus inhibits the TLR4 inflammatory signaling triggered by enterotoxigenic Escherichia coli via modulation of the negative regulators and involvement of TLR2 in intestinal Caco-2 cells and pig explantsPredominant effect of host genetics on levels of Lactobacillus johnsonii bacteria in the mouse gut.Probiotics: The scientific evidence in the context of inflammatory bowel disease.Hsp10, Hsp70, and Hsp90 immunohistochemical levels change in ulcerative colitis after therapy.Scientific evidence for health effects attributed to the consumption of probiotics and prebiotics: an update for current perspectives and future challenges.Alterations in fecal microbiota composition by probiotic supplementation in healthy adults: a systematic review of randomized controlled trials.Vitamin D associates with improved quality of life in participants with irritable bowel syndrome: outcomes from a pilot trial.Integrative medicine and human health - the role of pre-, pro- and synbioticsActual concept of "probiotics": is it more functional to science or business?Role of commensal and probiotic bacteria in human health: a focus on inflammatory bowel diseaseEffect of type of TAG fatty acids on lutein and zeaxanthin bioavailability.Impact of maternal supplementation with probiotics during pregnancy on atopic eczema in childhood--a meta-analysis.Role of the microbiota in inflammatory bowel diseases.Two faces of microbiota in inflammatory and autoimmune diseases: triggers and drugs.Challenges in translational research on probiotic lactobacilli: from in vitro assays to clinical trials.Monitoring immune modulation by nutrition in the general population: identifying and substantiating effects on human health.Pathomechanisms of Oxidative Stress in Inflammatory Bowel Disease and Potential Antioxidant Therapies.Lactobacillus acidophilus La5 and Bifidobacterium lactis Bb12 induce different age-related metabolic profiles revealed by 1H-NMR spectroscopy in urine and feces of mice.Amelioration of DSS-induced murine colitis by VSL#3 supplementation is primarily associated with changes in ileal microbiota composition.Probiotics can alleviate cardiopulmonary bypass-induced intestinal mucosa damage in rats.The potential synergistic behaviour of inter- and intra-genus probiotic combinations in the pattern and rate of short chain fatty acids formation during fibre fermentation.The TRPV1 channel in rodents is a major target for antinociceptive effect of the probiotic Lactobacillus reuteri DSM 17938.Lactobacillus plantarum surface layer adhesive protein protects intestinal epithelial cells against tight junction injury induced by enteropathogenic Escherichia coli.Lactobacillus plantarum consumption increases PepT1-mediated amino acid absorption by enhancing protein kinase C activity in spontaneously colitic mice.
P2860
Q21263105-95399DE3-926A-418E-954D-3FE52D94141FQ26777641-EE7DF9D7-5228-4B4D-8B79-F8ED6722FE37Q28743610-6796A02D-7143-4F8D-A314-5E2B140B37E7Q33904884-31051B81-90F8-4142-A96A-48C8F4949BA1Q34626740-07100667-A8D2-4213-96D7-B8555046CB1EQ34647736-25837BB7-9C59-4EC8-A7F4-5E0DE50646FCQ34664102-58D1FB15-26F2-4D15-BF6E-3A891CF16F2AQ34883210-EE46143C-5FF0-47D7-B5EC-4B9B9303CF8AQ35148077-DC5428C7-EE89-4C9A-BDBB-911F1116FBC2Q35271907-20F8F6F4-AD3C-4C75-BAA2-CAA953EE4C70Q35637895-0F5BFFA0-FF63-40D9-86F3-956705A5891AQ35771429-9787571B-8A90-492C-B7FC-5AE74D2576ABQ35800667-4F1B567A-FB9D-479F-892E-5954CC85F532Q36012463-70790E30-E322-4B31-85F7-316800B51956Q36405806-B01238B7-8C76-42DA-8B89-5743DE402F86Q36555442-08ED6974-718A-4489-8325-61778E9CD8ABQ36699182-3ED24B78-4828-4ADC-A9EA-C8DB675BB24CQ37053638-19B64067-7AC4-42EC-8E4D-2494DF8B27C4Q37072738-5789E454-7432-4F17-990A-3E96A5087B7CQ37905185-5A740CA1-7B35-43D0-A00C-CDA5CEBCDB78Q37936393-4683D8B0-A7C9-4AD1-8506-13F342664A26Q38055197-455DE504-FCBB-4054-8CBD-B813945FB6C1Q38084051-EDDEEB30-3289-4EDE-9144-6293E33ABF12Q39370979-94261154-0826-4B6D-BA51-0D3DD026F106Q39458419-9CFC513E-87CF-4B8C-937F-64F0CD8C5429Q44660774-9874B389-B330-493F-8895-824123877BA1Q44967584-7E64B999-D475-434A-A503-05F560656EB7Q46083282-7142CA1A-097E-4EA6-835F-645163B633D0Q46343224-CBA2F253-438A-4F9E-B3A9-F90C88E37F17Q48124178-E843CD98-2A0A-4058-AC14-534AC07B6ADFQ52605186-A1744BB9-CE80-4857-A1B3-EA4FF87603B3Q54637805-89899862-2B55-4F6C-B604-144C73B555AB
P2860
Guidance for substantiating the evidence for beneficial effects of probiotics: probiotics in chronic inflammatory bowel disease and the functional disorder irritable bowel syndrome.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 27 January 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Guidance for substantiating th ...... rder irritable bowel syndrome.
@en
Guidance for substantiating th ...... rder irritable bowel syndrome.
@nl
type
label
Guidance for substantiating th ...... rder irritable bowel syndrome.
@en
Guidance for substantiating th ...... rder irritable bowel syndrome.
@nl
prefLabel
Guidance for substantiating th ...... rder irritable bowel syndrome.
@en
Guidance for substantiating th ...... rder irritable bowel syndrome.
@nl
P2860
P50
P921
P356
P1433
P1476
Guidance for substantiating th ...... rder irritable bowel syndrome.
@en
P2093
Ger T Rijkers
Jean-Michel Antoine
P2860
P304
P356
10.3945/JN.109.113746
P407
P577
2010-01-27T00:00:00Z